Satya Prakash Yadav, Director of Pediatric Hematology Oncology and Bone Marrow Transplant at Medanta, shared a post on X by Nico Gagelmann, Co-founder and Co-chair of the European Society for Blood and Marrow Transplantation, adding:
“2024 blockbuster Menin inhibitor for infant ALL.”
Quoting Nico Gagelmann’s post about a paper by Ghayas Issa et al. published in Journal of Clinical Oncology:
“Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
- febrile neutropenia (1/3), differentiation syndrome (16%), QTc prolongation (14%)
- CR and CRh rate was 23%
- 2/3 with no detectable residual disease.”
Authors: Ghayas Issa et al.
More posts featuring Satya Prakash Yadav and Nico Gagelmann.
Nico Gagelmann is a physician and scientist who co-founded and co-chairs the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, and he also serves as the chair of the EBMT subcommittee focused on CAR-T cell therapies for plasma cell disorders.
His work is particularly impactful in the realm of CAR-T treatments for multiple myeloma, where he has contributed to advancing research and clinical approaches.